WallStSmart

Veradermics, Incorporated (MANE)vsRoyalty Pharma Plc (RPRX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

RPRX leads profitability with a 33.9% profit margin vs 0.0%. RPRX earns a higher WallStSmart Score of 65/100 (C+).

MANE

Avoid

25

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 3/9

RPRX

Buy

65

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 4.0Quality: 5.0
Piotroski: 2/9Altman Z: 1.15
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for MANE.

RPRXSignificantly Overvalued (-59.6%)

Margin of Safety

-59.6%

Fair Value

$34.38

Current Price

$55.02

$20.64 premium

UndervaluedFair: $34.38Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MANE0 strengths · Avg: 0/10

No standout strengths identified

RPRX3 strengths · Avg: 9.3/10
Profit MarginProfitability
33.9%10/10

Keeps 34 of every $100 in revenue as profit

Operating MarginProfitability
100.3%10/10

Strong operational efficiency at 100.3%

EPS GrowthGrowth
23.2%8/10

Earnings expanding 23.2% YoY

Areas to Watch

MANE4 concerns · Avg: 3.8/10
Price/BookValuation
9.2x4/10

Trading at 9.2x book value

Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

RPRX4 concerns · Avg: 3.5/10
PEG RatioValuation
2.054/10

Expensive relative to growth rate

P/E RatioValuation
28.9x4/10

Moderate valuation

Debt/EquityHealth
1.303/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MANE

MANE has a balanced fundamental profile.

Bull Case : RPRX

The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.

Bear Case : MANE

The primary concerns for MANE are Price/Book, Revenue Growth, EPS Growth.

Bear Case : RPRX

The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.

Key Dynamics to Monitor

MANE profiles as a value stock while RPRX is a mature play — different risk/reward profiles.

RPRX is growing revenue faster at 11.0% — sustainability is the question.

RPRX generates stronger free cash flow (761M), providing more financial flexibility.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

RPRX scores higher overall (65/100 vs 25/100), backed by strong 33.9% margins and 11.0% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Veradermics, Incorporated

HEALTHCARE · BIOTECHNOLOGY · USA

Veradermics, Incorporated is a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company is headquartered in New Haven, Connecticut.

Royalty Pharma Plc

HEALTHCARE · BIOTECHNOLOGY · USA

Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.

Visit Website →

Want to dig deeper into these stocks?